105 related articles for article (PubMed ID: 10715517)
1. Biochemical analysis of HLA class I subunits expression in breast cancer tissues.
Pistillo MP; Nicolò G; Salvi S; Capanni P; Perdelli L; Pasciucco G; Ferrara GB
Hum Immunol; 2000 Apr; 61(4):397-407. PubMed ID: 10715517
[TBL] [Abstract][Full Text] [Related]
2. Investigation of HLA class I downregulation in breast cancer by RT-PCR.
Palmisano GL; Pistillo MP; Capanni P; Pera C; Nicolò G; Salvi S; Perdelli L; Pasciucco G; Ferrara GB
Hum Immunol; 2001 Feb; 62(2):133-9. PubMed ID: 11182222
[TBL] [Abstract][Full Text] [Related]
3. Altered expression of HLA class I antigens in breast cancer: association with prognosis.
Gudmundsdóttir I; Gunnlaugur Jónasson J; Sigurdsson H; Olafsdóttir K; Tryggvadóttir L; Ogmundsdóttir HM
Int J Cancer; 2000 Nov; 89(6):500-5. PubMed ID: 11102894
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex status in breast carcinogenesis and relationship to apoptosis.
Redondo M; García J; Villar E; Rodrigo I; Perea-Milla E; Serrano A; Morell M
Hum Pathol; 2003 Dec; 34(12):1283-9. PubMed ID: 14691914
[TBL] [Abstract][Full Text] [Related]
5. The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer.
Bijen CB; Bantema-Joppe EJ; de Jong RA; Leffers N; Mourits MJ; Eggink HF; van der Zee AG; Hollema H; de Bock GH; Nijman HW
Int J Cancer; 2010 Mar; 126(6):1417-27. PubMed ID: 19728333
[TBL] [Abstract][Full Text] [Related]
6. HLA class I molecules expression: evaluation of different immunocytochemical methods in malignant lesions.
Facoetti A; Capelli E; Nano R
Anticancer Res; 2001; 21(4A):2435-40. PubMed ID: 11724304
[TBL] [Abstract][Full Text] [Related]
7. Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases.
Maiorana A; Cesinaro AM; Fano RA; Collina G
Clin Exp Metastasis; 1995 Jan; 13(1):43-8. PubMed ID: 7820955
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte antigen G expression in breast cancer: role in immunosuppression.
Elliott RL; Jiang XP; Phillips JT; Barnett BG; Head JF
Cancer Biother Radiopharm; 2011 Apr; 26(2):153-7. PubMed ID: 21510769
[TBL] [Abstract][Full Text] [Related]
9. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients.
de Kruijf EM; Sajet A; van Nes JG; Natanov R; Putter H; Smit VT; Liefers GJ; van den Elsen PJ; van de Velde CJ; Kuppen PJ
J Immunol; 2010 Dec; 185(12):7452-9. PubMed ID: 21057081
[TBL] [Abstract][Full Text] [Related]
10. Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide.
Perosa F; Luccarelli G; Prete M; Favoino E; Ferrone S; Dammacco F
J Immunol; 2003 Aug; 171(4):1918-26. PubMed ID: 12902494
[TBL] [Abstract][Full Text] [Related]
11. HLA class I antigen expression is associated with a favorable prognosis in early stage non-small cell lung cancer.
Kikuchi E; Yamazaki K; Torigoe T; Cho Y; Miyamoto M; Oizumi S; Hommura F; Dosaka-Akita H; Nishimura M
Cancer Sci; 2007 Sep; 98(9):1424-30. PubMed ID: 17645781
[TBL] [Abstract][Full Text] [Related]
12. Analysis and clinical relevance of human leukocyte antigen class I, heavy chain, and beta2-microglobulin downregulation in breast cancer.
Morabito A; Dozin B; Salvi S; Pasciucco G; Balbi G; Laurent S; Pastorino S; Carli F; Truini M; Bruzzi P; Del Mastro L; Pistillo MP
Hum Immunol; 2009 Jul; 70(7):492-5. PubMed ID: 19410618
[TBL] [Abstract][Full Text] [Related]
13. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma.
Kleinberg L; Flørenes VA; Skrede M; Dong HP; Nielsen S; McMaster MT; Nesland JM; Shih IeM; Davidson B
Virchows Arch; 2006 Jul; 449(1):31-9. PubMed ID: 16541284
[TBL] [Abstract][Full Text] [Related]
14. Class I HLA folding and antigen presentation in beta 2-microglobulin-defective Daudi cells.
Martayan A; Sibilio L; Tremante E; Lo Monaco E; Mulder A; Fruci D; Cova A; Rivoltini L; Giacomini P
J Immunol; 2009 Mar; 182(6):3609-17. PubMed ID: 19265139
[TBL] [Abstract][Full Text] [Related]
15. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer.
Kaklamanis L; Leek R; Koukourakis M; Gatter KC; Harris AL
Cancer Res; 1995 Nov; 55(22):5191-4. PubMed ID: 7585572
[TBL] [Abstract][Full Text] [Related]
16. Analysis of HLA-E expression in human tumors.
Marín R; Ruiz-Cabello F; Pedrinaci S; Méndez R; Jiménez P; Geraghty DE; Garrido F
Immunogenetics; 2003 Feb; 54(11):767-75. PubMed ID: 12618909
[TBL] [Abstract][Full Text] [Related]
17. Recognition of breast cancer-associated peptides by tumor-reactive, HLA-class I restricted allogeneic cytotoxic T lymphocytes.
Nguyen T; Naziruddin B; Dintzis S; Doherty GM; Mohanakumar T
Int J Cancer; 1999 May; 81(4):607-15. PubMed ID: 10225452
[TBL] [Abstract][Full Text] [Related]
18. Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines.
Jabrane-Ferrat N; Faille A; Loiseau P; Poirier O; Charron D; Calvo F
Int J Cancer; 1990 Jun; 45(6):1169-76. PubMed ID: 2112515
[TBL] [Abstract][Full Text] [Related]
19. [Tissue expression of antigenic recognition and intercellular adhesion molecules in chronic viral hepatitis].
García Monzón C; García Buey L; García Sánchez A; de Castro Marinas M; Muñoz Gómez R; Pajares JM; González Mateos F; Moreno Otero R
Rev Esp Enferm Dig; 1993 Nov; 84(5):301-9. PubMed ID: 7508239
[TBL] [Abstract][Full Text] [Related]
20. Human cytomegalovirus-encoded US2 differentially affects surface expression of MHC class I locus products and targets membrane-bound, but not soluble HLA-G1 for degradation.
Barel MT; Ressing M; Pizzato N; van Leeuwen D; Le Bouteiller P; Lenfant F; Wiertz EJ
J Immunol; 2003 Dec; 171(12):6757-65. PubMed ID: 14662880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
